Beta Bionics, Inc.

NASDAQ:BBNX

Medical - Equipment & Services

Healthcare
$14.33 +3.18%

+$0.42 today

Market cap
$644.70M
Beta
3.39
P/E (TTM)
-9.1
EPS (TTM)
-$1.50
52W Low $8.80High $32.71

Volume 1.38M

Average 0.99M

BBNX Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Beta Bionics, Inc.NASDAQ: BBNX

Net Debt · Q1 FY2026 · quarter ended Mar 2026

Net debt remains negative

Q1 FY2026 net debt was -$23.29M, compared with -$35.48M a year earlier.

Context

  • Net debt amounted to 7.7% of total assets at the end of Q1 FY2026, down 2.8 pp from a year earlier.
  • Net debt grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net debt keeps rising in the next quarterly balance sheet after a +34.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$23.29M+4.0% QoQ
Last fiscal yearDec 2025
-$24.27M-4.7% YoY
Year agoMar 2025
-$35.48M+34.3% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+34.3%——
1 year-4.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Debt history

USD · from the balance sheet

Latest · FY2025
(24.27M) USD
Year-over-year change
-4.7%

Net Debt vs competitors

How BBNX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +34.3% is the 3rd highest of 7, against a peer median of +22.3%.
  • Net debt amounts to 7.7% of total assets for BBNX, versus a peer median of 13.1%.
BBNX Competitors
Net Debt for BBNX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NVONovo Nordisk A/SJun 2026DKK 95.65B DKK+18.3%+99.6%16.1%
TNDMTandem Diabetes Care, Inc.Mar 2026$555.41M USD+26.3%+12.7%48.2%
PODDInsulet CorporationJun 2026$413.5M USD-2.6%-25.5%13.1%
MNKDMannKind CorporationMar 2026$383.84M USD+619196.8%+22.2%51.6%
DXCMDexCom, Inc.Jun 2026$293.4M USD-79.3%-32.0%4.5%
ORMPOramed Pharmaceuticals Inc.Mar 2026-$12.44M USD+83.2%—4.6%
BBNXBeta Bionics, Inc.Mar 2026-$23.29M USD+34.3%—7.7%
MMEDMiniMed Group, Inc. Common StockJul 2026-$148M USD——3.1%
Peer median (excluding BBNX) —+22.3%+12.7%13.1%

Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents27.68M26.57M30.43M31.58M
Short-term Investments070.18M73.14M187.55M
Net Receivables04.45M12M19.89M
Inventory01.25M13.32M21.72M
Other Current Assets250K275K1.05M100K
Total Current Assets28.47M103.62M132.92M267.91M
Property, Plant & Equipment (Net)6.87M6.2M11.42M15.23M
Goodwill0000
Intangible Assets0000
Long-term Investments00045.43M
Tax Assets0000
Other Non-current Assets193K221K5.3M180K
Total Non-current Assets7.06M6.42M16.72M60.84M
Total Assets35.53M110.04M149.65M328.74M
Account Payables430K1.17M2.85M5M
Short-term Debt0000
Tax Payables0000
Deferred Revenue087K939K1.56M
Other Current Liabilities1.32M1.14M10.94M14.59M
Total Current Liabilities8.87M10.61M21.15M30.92M
Long-term Debt0000
Deferred Tax Liabilities0000
Deferred Revenue (Non-current)0255K1.86M3.3M
Other Non-current Liabilities10.5M37.83M44.9M1.55M
Total Non-current Liabilities13.65M40.83M52.48M10.21M
Total Liabilities22.53M51.43M73.63M41.13M
Common Stock1K1K1K4K
Retained Earnings(185.57M)(229.66M)(296.74M)(369.94M)
Accumulated OCI0137K65K403K
Other Stockholders Equity0000
Minority Interest0000
Total Equity13M58.61M76.01M287.61M
Total Debt4.13M4.22M7.26M7.3M
Net Debt(23.54M)(22.34M)(23.18M)(24.27M)

Beta Bionics, Inc.

NASDAQ:BBNX

Intrinsic Alpha fair value

Locked

Current Price

$14.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.